Thyrocare Technologies Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Thyrocare reported consolidated revenue growth of 24.3% and standalone revenue growth of 26.1% in Q1 FY27, with pathology business revenue growing 26% year-on-year. Management highlighted the commercial launch of its Specialty Diagnostics business covering allergy and genomics testing, alongside continued growth in franchisee and partnership channels. The company also discussed a planned divestment of its radiology/nuclear business and updates on franchisee network expansion.
Thyrocare reported consolidated revenue of Rs 224 crore for Q4 FY26, up 20% year-on-year, with full-year consolidated revenue at Rs 829 crore, up 21%. EBITDA margin for the quarter was 34% and profit after tax grew 128% year-on-year to Rs 48.7 crore. Management discussed expansion into genomics and allergy testing, growth in franchisee and partnership channels, and a final dividend of Rs 7 per equity share.